Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

Table 4

Glycemic control and pancreatic β-cell function.

	Baseline	4 weeks after treatment
Insulin dose (IU/d)			0.000
HbA1c (%)			0.000
FBG (mmol/L)			0.015
PBG 30 min (mmol/L)			0.004
PBG 120 min (mmol/L)			0.005
C-peptide 0 min (ng/mL)			0.589
C-peptide 30 min (ng/mL)			0.372
C-peptide 120 min (ng/mL)			0.382
HOMA-CR			0.543
HOMA-beta			0.046

Data were shown as or median (first quartile, third quartile). Baseline vs. 4 weeks after the treatment: . HbA1c: glycosylated hemoglobin; FBG: fasting blood glucose; PBG 30 min: postprandial blood glucose at 30 min after a standard meal; PBG 120 min: postprandial blood glucose at 120 min after a standard meal; C-peptide 0 min: C-peptide level at 0 min after a standard meal; C-peptide 30 min: C-peptide level at 30 min after a standard meal; C-peptide 120 min: C-peptide level at 120 min after a standard meal; HOMA-CR: homeostasis model assessment of C-peptide secretion; HOMA-beta: homeostasis model assessment for pancreatic beta-cell.